{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012004","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.866220+00:00","generated_at":"2026-05-15T23:58:33.056513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Delcath reports FY2025 revenue $85.2M, net income $2.7M; guides FY2026 revenue ≥$100M","bullets":["FY2025 total revenue $85.2M, up 129% YoY ($37.2M); HEPZATO revenue $78.8M, CHEMOSAT $6.4M.","Full-year net income $2.7M vs net loss $26.4M in 2024; adjusted EBITDA $25.1M.","Cash $91.0M, no debt; repurchased 628,572 shares for $6.0M.","FY2026 guidance: total revenue at least $100M, HEPZATO volume growth ≥20%, gross margin 84-87%.","28 active centers; 140% procedure volume growth in 2025; publications including CHOPIN study."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012004","json":"https://secwatch.observer/filing/0001628280-26-012004.json","markdown":"https://secwatch.observer/filing/0001628280-26-012004.md","text":"https://secwatch.observer/filing/0001628280-26-012004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828026012004/0001628280-26-012004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828026012004/dcth-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:58:33.056513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}